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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idBacterial sexually transmitted infections (STI’s), such as
syphilis, chlamydia, and gonorrhea, remain highly prevalent
around the globe with rising incidence rates in many at-risk
populations. Additionally, hepatitis B and C continue to cause
signiﬁcant mortality and morbidity throughout the world. While
hepatitis B and C are treatable, and therapies for chronic hepatitis C
are advancing at a dizzying pace, many individuals remain
undiagnosed and continue to transmit these infections to
susceptible persons. Therefore, opportunities for screening and
treatment of bacterial STI’s and viral hepatitis are invaluable. Visits
for nonoccupational postexposure prophylaxis (nPEP), whether in
the emergency department or clinic, provide a crucial opportunity
for screening, counseling, and prevention. To date, data on this
topic are scant and primarily focus on HIV PEP.
For these reasons, the study by Sivachandran and colleagues in
this edition of the International Journal of Infectious Diseases is a
welcome addition to the nPEP literature.1 The authors prospectively
followed 126 individuals who presented to a dedicated HIV
prevention clinic after a nonoccupational exposure (approximately
70% were sexual exposures). The analysis concentrates on screening
practices, diagnosis rates, and follow-up for bacterial STI’s and viral
hepatitis, and provides several notable ﬁndings. First, nearly 5% of
participants were diagnosed with a bacterial STI (including one
person who presented for a non-sexual exposure). Second, while no
cases of hepatitis C seroconversion occurred during follow-up,
hepatitis C was detected in 2.4% at baseline. Interestingly, all
individuals diagnosed with an infection in this cohort were men
(about three quarters of participants overall were male). Finally,
22.2% of participants did not have protective levels of hepatitis B
surface antibody at baseline and only approximately half of these
individuals were retained in care long enough to complete a vaccine
series or booster dose and conﬁrm seroprotection.
What lessons can be learned from this analysis? The principal
message is that nPEP visits provide an opportunity for more than
HIV PEP. These encounters provide an important moment in which
bacterial STI’s and viral hepatitis can be addressed. While it is vital
to assess the risk of HIV transmission and consider the need for HIV
PEP, this study underscores the need to consider other infections.
For example, identifying baseline chronic hepatitis C and linking a
person to hepatitis C care can be life-saving; even if a person is not
ready for treatment, steps can be taken to prevent worsening liverDOI of original article: http://dx.doi.org/10.1016/j.ijid.2015.10.001
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1201-9712/ 2015 The Author. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ﬁbrosis or hepatic decompensation (through alcohol reduction
counseling and vaccination against hepatitis A and B), the degree of
liver ﬁbrosis can be assessed and complications of cirrhosis
managed, and a person can be counseled to reduce risk of
transmission to others. Furthermore, men or women diagnosed
with a bacterial STI should be considered for HIV preexposure
prophylaxis (PrEP) and linked to PrEP services. Men-who-have-
sex-with-men (MSM) diagnosed with a bacterial STI are one of the
highest risk groups for HIV infection; STI treatment may decrease
the likelihood of HIV infection if there is ongoing risk behavior, but
linkage to PrEP services is also essential for HIV prevention.2,3
The current study highlights the issue of retention in care for
individuals who present for nPEP and the difﬁculty engaging these
patients in preventive health services. Attrition between ED visits
for nPEP and follow-up in the clinic is a major area of concern.
Previous reports showed that only 54.4% of individuals who
present to the ED for nPEP keep their follow-up visit in clinic.4 The
study by Sivachandran and colleagues adds insight into the
challenge of retaining nPEP patients for the full course of follow-up
and underscores that strategies to support linkage and retention in
care for nPEP patients are needed.
The HIV Care Continuum provides a representation of the stages
of HIV care from diagnosis to achievement of viral suppression and
illustrates the proportion of individuals lost at each stage.5 This
care continuum has been replicated in many countries and offers a
tool to optimize prevention efforts and allocation of resources.6,7 A
similar care cascade for hepatitis C depicts the drastic divide
between the number infected and the number who have been
successfully treated.8,9 Researchers have also generated a care
cascade as it stands for PrEP in certain areas.10 Although it would
be difﬁcult to measure or assess, one can imagine what a care
continuum for nPEP might look like and the substantial number of
individuals lost at each step: from the number exposed, to the
proportion who present for initial evaluation, to the proportion
who adhere to a follow-up clinic visit, to the proportion who ﬁnish
their nPEP medications and vaccines (if recommended), and ﬁnally
to those who complete nPEP follow-up or successfully transition to
PrEP (if indicated). Such a model provides an idea of the most
effective areas to dedicate adherence support resources.
Practitioners who provide postexposure care anywhere in the
world know that many individuals who present for nPEP are likely
to do so again in the future; per one study, nearly one ﬁfth of nPEP
users had multiple nPEP courses.11 These individuals would
beneﬁt signiﬁcantly from the type of ‘‘wrap around’’ servicesiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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many clinics for years. The authors of the current study suggest
automated reminders to support nPEP adherence, which would be
a useful step, though additional outreach is likely needed. Other
authors have stressed the importance of adherence counseling that
addresses mental health and psychosocial barriers.12 A working
group recently developed a list of priority areas for PEP research
and the list includes identiﬁcation of barriers to accessing care and
trials to assess the effectiveness of various adherence support
strategies.13 The working group also emphasizes that lessons can
be learned from HIV treatment and PrEP adherence trials. The
current study reminds us that key components of nPEP adherence
include PEP medications as well as follow-up visits, vaccinations
and lab testing, and linkage to PrEP services.
The current study has several limitations. It is a single-center
study, so additional analyses from other geographic regions and
patient populations are needed. Testing for STI’s included
screening of the pharynx and rectum for MSM, which is important,
though did not use nucleic acid ampliﬁcation testing (NAAT), so
some extragenital chlamydia and gonorrhea infections in MSM
may have been missed.14–16 The study did not identify any STI’s in
women, though did not test for trichomoniasis, a common yet
underreported STI throughout the world. Despite these limitations,
the authors should be commended for their efforts and this
analysis should encourage other centers to examine their nPEP
practices and support systems.
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